Symetis to be bought by Boston Scientific for $435 million
Summary
The acquisition of Symetis by Boston Scientific will allow the company to extend its reach and expand the treatment offerings for patients with aortic valvular heart disease worldwide. The IPO that we were pursuing until yesterday on Euronext Paris was meant to give Symetis the means to commercially expand beyond Europe and to further grow into the exciting field of structural heart. The global scale and strong legacy of Boston Scientific in interventional cardiology will further propel Symetis clinical excellence. This purchase agreement is a recognition of Symetis research and development track record in addressing patients needs with innovative structural heart technologies, the companys manufacturing expertise and its strong relationships with doctors and healthcare professionals. We are excited about the strong potential of our combined strengths to set a new standard in the TAVI market with a broad and clinically differentiated offering."